Study of Over 8,300 Chronic Pain Patients Finds Medical Marijuana Use Linked to Twice the Rate of Opioid Prescription Discontinuation

Patients with chronic pain who received medical marijuana for more than 30 days were approximately twice as likely to discontinue prescription opioids as those who received marijuana for a shorter period, according to a new study published in the Journal of Addiction Medicine.

The study, published October 28, examined 8,358 patients in New York who were receiving long-term opioid therapy for chronic pain and had also obtained medical marijuana. Researchers found that 15.5% of patients receiving medical marijuana for more than 30 days discontinued opioid prescriptions, compared with 7.6% of those receiving marijuana for 30 days or less.

Researchers analyzed records from New York State’s Medical Cannabis Program and Prescription Monitoring Program covering 2017 through 2019. Patients were followed for 90 days, with opioid discontinuation defined as a gap of at least 45 days without an opioid prescription.

Of the patients studied, 4,892 received medical marijuana for more than 30 days, while 3,466 received it for 30 days or less. The difference in opioid discontinuation between the groups was statistically significant.

The association was particularly strong among patients receiving lower or moderate opioid doses before beginning medical marijuana treatment.

For patients taking less than 50 morphine milligram equivalents (MME) daily, those receiving medical marijuana for longer periods had an adjusted opioid discontinuation rate 2.87 times higher during the first 30 days of follow-up. After the first 30 days, the adjusted rate remained 1.81 times higher.

Among patients receiving between 50 and less than 90 MME daily, the adjusted rate of discontinuation was 3.13 times higher in the longer-duration marijuana group throughout the follow-up period.

However, researchers found no statistically significant association between medical marijuana exposure and opioid discontinuation among patients receiving 90 MME or more daily, suggesting the relationship may differ depending on a patient’s existing opioid dosage.

The research adds to previous findings from New York examining medical marijuana and prescription opioid use. A 2023 study published in JAMA Network Open, which analyzed more than 8,100 patients using the same years of state records, found that longer periods of medical marijuana use were associated with reductions in prescribed opioid dosages.

The newly published analysis examines a different outcome: whether patients stopped receiving opioid prescriptions altogether rather than simply reducing their doses.

Because the research was observational, it cannot establish that medical marijuana directly caused patients to discontinue opioids. The prescription records also do not establish whether patients experienced improvements in pain or whether discontinuation was medically supervised.

Nevertheless, the findings provide additional evidence of an association between sustained medical marijuana treatment and reduced reliance on prescription opioids among chronic pain patients, particularly those receiving less than 90 MME daily.